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Abstract 46 
Infection is a common complication of cystic fibrosis (CF) airways disease. Current 47 
treatment approaches include early intervention with the intent to eradicate 48 
pathogens in the hope of delaying development of chronic infection and chronic use 49 
of aerosolized antibiotics to suppress infection.  The use of molecules that help 50 
restore CFTR function, modulate pulmonary inflammation, or improve pulmonary 51 
clearance, may also influence the microbial communities in the airways.  As the 52 
pipeline of these new entities continues to expand, it is important to define when key 53 
pathogens are eradicated from the lungs of CF patients and equally important, when 54 
new pathogens might emerge as a result of these novel therapies. 55 
 56 
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Predicted median life expectancy for people with cystic fibrosis (CF) is now reaching 72 
into the 5th decade (1).  This dramatic rise is attributable to numerous research 73 
advances resulting in an improved understanding of the biology of CFTR (cystic 74 
fibrosis transmembrane conductance regulator) dysfunction and its consequences 75 
for innate immunity resulting in chronic infection, inflammation and lung damage.  76 
This knowledge has successfully translated into a variety of new treatments which 77 
have disease modifying potential.  78 
 79 
Antimicrobial therapy to eradicate initial or repeated episodes of Pseudomonas 80 
aeruginosa positive sputum delays onset of chronic P. aeruginosa infection 81 
improving life expectancy (2,3).  Other interventions that have contributed to 82 
improved life expectancy include: development of agents to help restore CFTR 83 
function; interventions to improve nutrition; using azithromycin as an 84 
immunomodulator; improving pulmonary clearance with ancillary mucoactive 85 
therapies such as hypertonic saline, DNAse and/or inhaled mannitol; infection control 86 
strategies; and as a last resort, lung transplantation (2,3,4).  However, median 87 
predicted survival for CF patients is still substantially lower than that of the general 88 
population. The destruction of lung architecture, secondary to inflammation in 89 
response to chronic infection, is the major contributor to this shortened life span.  90 
Although advances in antimicrobial therapy have contributed significantly to 91 
increased life expectancy, they have also resulted in the emergence of multi-drug-92 
resistant organisms that currently limits the long term effectiveness of this important 93 
treatment strategy (5). 94 
 95 
As additional solutions for the care and treatment of CF patients are studied, an 96 
international working group of CF care providers, epidemiologists, and medical 97 
microbiologists gathered to address two questions which are important in 98 
considering the implementation of new antimicrobial agents: (i). when has a specific 99 
pathogen been eradicated from CF airways in an individual?; and (ii) when has an 100 
organism emerged as a pathogen in people with CF  either de novo or as a result of 101 
these novel therapeutic approaches? 102 
 103 
Defining “pathogen eradication” in individuals 104 
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Much of the improvement in life expectancy in people with CF is predicated on 105 
understanding how to prevent the establishment of chronic pulmonary infection. The 106 
major respiratory pathogen is a distinctive phenotype of P. aeruginosa referred to as 107 
“mucoid” (1). Mucoid strains of P. aeruginosa are highly adapted to grow in the CF 108 
airway.  Key features of mucoid P. aeruginosa is a biofilm mode of growth that 109 
makes the organism refractory to innate immunity and antimicrobial therapy and a 110 
hypermutator phenotype which results in increased antimicrobial resistance (1, 6).  111 
The initial steps of the establishment of chronic infection with mucoid P. aeruginosa 112 
is colonization/infection with a non-mucoid strain (1,3).  Genotyping studies suggest 113 
that initial colonization/infection is due to unique P. aeruginosa strains arising from 114 
the environment, although individuals may be infected with similar strains (6,7,8).  115 
However, what is less clear is whether individuals with similar strains obtained them 116 
from the environment or via cross-infection from another person with CF.  Early 117 
studies showed that aggressive antimicrobial therapy of non-mucoid strains delayed 118 
the establishment of chronic infection (1,3).  Subsequently two large studies, EPIC 119 
(9) and ELITE (10) determined the efficacy of eradication of P. aeruginosa using 120 
aerosolized tobramycin in different regimens with (EPIC) or without (ELITE) oral 121 
ciprofloxacin.  Both were able to show that 28 days of aerosolized tobramycin alone 122 
led to negative cultures in approximately 90% of patients and the median time to 123 
next positive culture for P. aeruginosa was 2 years (9, 10). Adding ciprofloxacin, 124 
treating for longer duration (56 days), and routine treatment every 3 months did not 125 
improve outcomes.  Further data from the EPIC cohort shows that individuals that 126 
had sustained eradication of P. aeruginosa were less likely to develop chronic 127 
infection compared to those with early recurrence of infection (9).  The finding of a 128 
mucoid strain is a poor prognostic factor with a lower probability of eradication 129 
following therapy (11) and greater likelihood of having symptoms (2).  Taken 130 
together, these data support the notion  that regular culture of airways samples 131 
(surveillance cultures) beginning in infancy, with the express purpose of detecting P. 132 
aeruginosa during the early stages of infection, are an important standard of care for 133 
people with CF (2).  When a positive airway culture occurs, the current practice is to 134 
use aerosolized antimicrobials for a fixed duration to eradicate P. aeruginosa (12).  135 
Registry data showing a striking decline in P. aeruginosa prevalence in a number of 136 
countries attest to the effectiveness of this eradication strategy (13, 14, 15). The 137 
optimal antibiotics and duration of treatment has not been fully established, but a 138 
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prolonged treatment duration of three months compared to one month and the 139 
addition of oral antibiotics (16, 17) are not superior to one month of inhaled 140 
tobramycin.   141 
Other organisms that are pathogenic in the CF lung include members of the 142 
Burkholderia cepacia complex particularly Burkholderia cenocepacia, 143 
Staphylococcus aureus with methicillin resistant (MRSA) strains being observed with 144 
increasing frequency, and Mycobacterium abscessus (1,3).  MRSA is the only 145 
organism for which a multi-center eradication study has been attempted (18).  Here, 146 
a complex eradication scheme of oral antimicrobials, nasal mupirocin, chlorohexidine 147 
mouthwash and body wipes, and environmental cleaning including wiping 148 
environmental surfaces and weekly washing of towels and linens was employed. It 149 
was found that 54% of the CF subjects in the treatment arm remained free of MRSA 150 
after 12 weeks compared to 10% in the control population.  Owing to their low 151 
prevalence and limited antimicrobial choices due to resistance, multi-center 152 
eradication trials are not likely for either B. cepacia complex or M. abscessus (19,20) 153 
 154 
Eradication presumes that a target organism has been eliminated from the airways. 155 
To understand how eradication might be defined clinically, it is first important to 156 
understand how chronic infection is defined.  There have been a number of different 157 
definitions  of chronic CF lung infection (21).  These definitions are based on the 158 
persistent presence of a target organism e.g P. aeruginosa¸ and in some definitions, 159 
an antibody response to the organism of interest (21).  Since antibody tests are not 160 
widely available or standardized (22), most definitions used in clinical trials of chronic 161 
infections are based on sequential culture findings (9,10).  The most widely used 162 
definition of chronic CF lung infection is the Leed’s criteria (5, 23).  It has primarily 163 
been used to define chronic P. aeruginosa infection in CF children. CF persons are 164 
categorized as having no infection, being free of infection, intermittent infection, or 165 
chronic infection. The initial definition was based on “monthly” cultures but has 166 
evolved to one based upon the presence or absence of target organisms in four or 167 
more respiratory specimens collected in a 12 month period (21,23).  Patients defined 168 
as having intermittent infection comprise those who have cultures positive for a 169 
target organism in <50% of samples, with those defined as chronically infected target 170 
organism culture positive in >50% of specimens.   171 
 o
n
 August 23, 2018 by guest
http://jcm.asm.org/
D
ow
nloaded from
 
Some investigators advocate for the use of qPCR as a surrogate for traditional 172 
culture for a specific target organism using the rationale that it is more sensitive than 173 
culture, especially in individuals who are unable to expectorate sputum (24, 25, 26).  174 
One study showed, however, that qPCR could not differentiate between subjects in 175 
whom eradication was successful and those who failed (25).  As such, the utility of 176 
qPCR in eradication studies remains uncertain and requires further investigation.   177 
It is important to recognize that the meaning of eradication in the research setting 178 
likely has different meanings for the research scientist compared to the research 179 
subject.  The research subject should understand that eradication does not equal 180 
“cure” and that the primary goal of eradication treatment is to delay onset of chronic 181 
infection (9, 10, 11).  Most subjects will “fail” eradication efforts at some point in the 182 
future.  This failure may be the result of a recurrence of infection with the initial 183 
infecting agent or infection with a new strain of the same bacterial species (27). 184 
 185 
In CF clinical trials, the definition of “eradication” varies widely from a negative 186 
culture at one week to three negative cultures over at least a six-month period after 187 
treatment cessation (10,11,12,18, 28).  A definitive definition of “eradication”; would 188 
be valuable so that trials could be more easily compared. However, defining failure 189 
of eradication by a specific treatment is complicated by at least three factors.  First, 190 
in non-sputum producers especially children under five years of age, 191 
oropharyngeal/deep throat swabs are often used for culture.  Although these cultures 192 
tend to have good specificity, sensitivity is lacking meaning “false” eradication might 193 
be reported (29).  Secondly, it may be difficult to differentiate “failure of eradication” 194 
with re-infection with a new genotype of the same target organism.  Finally, the 195 
retention of indistinguishable genotypes in the oropharynx following successful lower 196 
airway antimicrobial therapy also raise important questions concerning upper airway 197 
reservoirs and how to best determine eradication in non-expectorating patients (7).  198 
Because oropharyngeal cultures are unreliable in reflecting what organisms are 199 
present in the lower airway, a second approach, a sinonasal washing may have 200 
value (29).  Although a positive P. aeruginosa sinonasal culture has a strong 201 
correlation with the finding of the organism in the lower tract, it has a sensitivity of 202 
only 66% meaning one-third of individuals with P. aeruginosa in the lower tract will 203 
be culture negative.  The accurate detection of P. aeruginosa in the lower respiratory 204 
tract using non-invasive techniques is challenging in the non-expectorating patient.  205 
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 206 
Eradication studies generally have not examined genotypes of the target organism 207 
prior to the initiation of therapy to enable comparison to the target organism isolate 208 
found post intervention. Moreover, they do not utilize multiple sampling strategies 209 
which assess both the upper and lower airway compartments.  These approaches 210 
would be necessary for differentiating failure to eradicate (i.e. persistence of infection 211 
with the same strain) from re-infection either with the same or a different strain of the 212 
organism.  This issue is further complicated by how many morphotypes should be 213 
genotyped pre- and post-intervention and what genotyping method should be used.  214 
Several PCR based methods have been used in molecular epidemiology studies of 215 
P. aeruginosa (7,8). The PCR-based method likely to offer the greatest 216 
discriminatory power is multi-locus sequence typing (MLST) (30).  Another widely 217 
used method is pulsed field gel electrophoresis (PFGE) (30, 31) which has the 218 
advantage of being a widely accepted typing scheme that has been used for a 219 
variety of molecular epidemiology applications (32, 33).  However, this technique is 220 
technically demanding and mutations, small insertions or deletions may cause 221 
organisms with the same genetic ancestry to appear to be distinct clones; whereas 222 
MLST is considered to be a more stable genotyping platform (30, 31).  Overall, 223 
whole genome sequencing (WGS) is regarded as the most discriminatory of all 224 
typing methods (34). Ideally, as WGS becomes less expensive and more widely 225 
accessible, it will become the method of choice for bacterial strain typing. A major 226 
barrier to using WGS typing as epidemiologic tool is how to define if isolates belong 227 
to a specific clone. , The number of single nucleotide polymorphisms (SNPs) that 228 
defines a clone varies from organism to organism. For example, Marvig et al (6) 229 
reported that P. aeruginosa isolates recovered from CF children and young adults of 230 
the same clone type differed by 122 SNPs, while different clone types differed 231 
>10000 SNPs.  By contrast, isolates of vancomycin-resistant enterococci (VRE) 232 
found to be indistinguishable by PFGE showed a diversity of <10 SNPs, 233 
indistinguishable MRSA isolates differed by <100 SNPs; whereas, unrelated VRE 234 
and MRSA PFGE types showed a divergence of approximately 4,000 and 20,000 235 
SNPs, respectively (34).  Before WGS method is adopted in clinical trials, clear 236 
definitions of what constitutes a clone and how many SNPs are necessary for 237 
isolates to be considered as unrelated clones needs to be determined.   238 
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As the development of novel CF therapies accelerate, a clear definition of what 239 
constitutes eradication.will allow for the design of rigorous studies that measure the 240 
effectiveness of these therapies and differentiate recurrence from re-infection with a 241 
different strain of the same organism.  For now, the following recommendations 242 
should be considered:- 243 
 244 
1. Eradication is best defined by obtaining multiple specimens (minimum of 3), 245 
over an extended time period (six months), all of which should all be negative for the 246 
target organism. 247 
2. Genotyping of multiple colony types` of specific target organisms should be 248 
done at enrollment by a highly discriminatory technique (preferably WGS but PFGE 249 
or MLST may be reasonable substitutes) and compared to any target organisms 250 
found post-intervention.  The number of isolates to be typed should be based on 251 
what is economically feasible.      252 
 253 
Defining population-level pathogen emergence 254 
 255 
The issue of when an organism “emerges” in a population has consequences for 256 
the use of novel therapeutics in CF patients.  The term “emerging pathogen” is one 257 
that is greatly overused in the literature.  This overuse most likely reflects the lack of 258 
a clear definition of what is an “emerging pathogen.”  Mathematically based 259 
definitions of “emerging pathogen”, for example using segmented linear regression, 260 
are retrospective, but nevertheless offer a definition of greater precision (35). A 261 
widely used definition would be a “clinically distinct condition whose incidence in 262 
humans has increased” (36), but that suggests one should establish the time horizon 263 
over which this increase has happened, the population affected, and how much of an 264 
increase there has been when declaring “emergence (37).”  265 
Pathogens that have emerged in CF patients according to this definition during the 266 
past four decades are members of the B. cepacia complex during the 1980s and 267 
MRSA during the first decade of this century.  In the early 1980s, three CF centers in 268 
North America reported a new organism in CF patients called, at that time, 269 
Pseudomonas cepacia (19).  This organism appeared to be truly novel causing a 270 
syndrome named the “cepacia syndrome” in which there was rapid pulmonary 271 
decline and in some cases bacteremia, a rare occurrence in people with CF, 272 
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resulting in death within months of infection but only rarely causing serious infection 273 
in other patient populations (20).  This syndrome was found to be primarily due to a 274 
single species, B. cenocepacia, which is one of the 21 different species eventually 275 
characterized within the B. cepacia complex (19, 38).  As molecular typing tools 276 
improved, centers where B. cenocepacia emerged were most often dominated by a 277 
single clone first recovered in a specific geographic locale (e.g. ET12 278 
(Edinburgh/Toronto), PHDC, and Midwest strains) (18,20).  The ET12 strain has 279 
subsequently been found throughout Canada, the United Kingdom and Ireland (18, 280 
20,39).  These B. cenocepacia strains, refractory to antimicrobial clearance, and able 281 
to be spread from person-to-person were eventually controlled by strict infection 282 
control practices.  283 
The use of selective media to isolate members of the B. cepacia complex coupled 284 
with the use of genomic (DNA sequencing) and proteomic (matrix-assisted laser 285 
desorption/ionization time-of-flight mass spectrometry or MALDI-TOF MS) identification 286 
techniques has resulted in the recognition of a number of “emerging” organisms 287 
(19,20).  With the use of aerosolized tobramycin, the frequency with which 288 
Stenotrophomonas maltophilia and Achromobacter spp., two organisms resistant to 289 
tobramycin, are detected has increased (13,20).  However, there is considerable 290 
debate as to whether either of these organisms are pathogens in chronic CF lung 291 
disease.  Some studies suggest that S. maltophilia is a pathogen in settings where it 292 
can be proven that the patient is mounting a humoral response to the organism (40, 293 
41,42); however, a large population-based study suggested otherwise (43). Similar 294 
data exists for Achromobacter spp suggesting that the organism is playing a 295 
pathogenic role in patients who mount a humoral response to it (20). Other much 296 
less frequently detected organisms (<1% prevalence) include Burkholderia gladioli, 297 
Burkholderia pseudomallei, Ralstonia spp., Chryseobacterium sp., Pandorea spp., 298 
and Inquilinus spp.) (19,20).  Insufficient longitudinal clinical data exists for people 299 
with CF infected with these organism in part due to the infrequency with which these 300 
organisms  are recovered. 301 
 302 
 303 
Another organism that has clearly emerged in CF persons has been MRSA in the 304 
United States during the first decade of this century.  Chronic MRSA infection in CF 305 
is associated with declining lung function and premature death (44).  Unlike B. 306 
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cenocepacia, the rise in MRSA in people with CF has paralleled the rise of MRSA in 307 
other US populations (13, 18, 45).  Interestingly, MRSA has not increased in other 308 
countries with robust CF registry data such as the United Kingdom and Australia 309 
both of whom have been better able to control MRSA spread in the general 310 
population (15, 45) 311 
Finally, the non-tuberculous mycobacteria (NTM) have also been described as 312 
“emerging” in people with CF.  However the presence of NTM in people with CF was 313 
first described in the early 1990s based on data gathered in part in the 1980s (46).  314 
NTM found in people with CF predominantly comprise Mycobacterium avium 315 
complex and M. abscessus isolates.  To say that an organism has “emerged,” there 316 
needs to be evidence of an increase in its incidence. The problem in describing 317 
these organisms as ‘emerging pathogens’ is that there are historic data suggesting 318 
that it has been present in adult CF persons for at least 30 years.  Increasing 319 
numbers of NTM infected CF persons in this century have been reported in the US, 320 
Israel, and Germany (47, 48, 49, 50).  In the US, data has been gathered in a 321 
systematic manner only over the past five years.  These data are further complicated 322 
by the fact that there is little standardization in how these organisms are detected 323 
and identified, thus making the data available of questionable value (47).  Part of the 324 
increased detection of these organisms is likely due to both increased clinical 325 
awareness and improved genomic and proteomic based identification techniques 326 
(20).  Another interesting possibility is that the combination of aggressive 327 
antimicrobial therapy over many years coupled with general improvements in overall 328 
health has created a CF adult population that is “primed” to be colonized/infected 329 
with environmental organisms that are highly resistant to antimicrobials.  Examples 330 
of such organisms include M. abscessus, MRSA, S. maltophilia and Achromobacter 331 
spp.(19,20)  332 
There are two intriguing observation concerning M. abscessus in CF lung disease 333 
that should be noted. First, there is a developing body of evidence that indicates that 334 
M. abscessus is associated with declining lung function in CF populations (49, 50) 335 
with the rate of pulmonary decline greater than seen with other CF pathogens (51).   336 
Secondly, a recent study has shown that a specific clone of M. abscessus may have 337 
spread globally (52).  Could this clone be analogous to the B. cenocepacia clones 338 
that emerged in the 1980s and the MRSA US300 clone that emerged in the early 339 
part of this century in CF patients?  Animal and in vitro studies suggest that this 340 
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strain demonstrates increased virulence when compared to other unique M. 341 
abscessus strains; however, further clinical and environmental studies are needed to 342 
determine its significance and origins (52). 343 
 344 
An important recent finding is the recognition that patients with chronic CF lung 345 
disease have a unique microbiome which is resilient to antibiotic treatment (53).  346 
Within the context of this observation are two important findings.  First, anaerobic 347 
bacteria and streptococci are frequently important components of this microbiome 348 
and changes in their relative abundance may be associated with pulmonary 349 
exacerbations (54,55,56,57).  Secondly, as lung function declines, there is a 350 
decrease in airway microbial community diversity with certain organisms 351 
predominating  (54,55,56,57,).  Not surprisingly, these predominant organisms are 352 
those considered the major CF pathogens and include P. aeruginosa, B. cepacia 353 
complex and S. aureus.  The role of NTM in the CF lung microbiome is presently 354 
unclear as challenges exist in their detection by current microbiome analysis 355 
methods. 356 
 357 
Microbiome analysis by next generation sequencing will provide greater 358 
understanding of CF lung microbial communities and should eventually provide 359 
information on how organism interactions result in lung pathology.  In the short term, 360 
the recognition of increased recovery of specific target organisms known to be 361 
associated with CF lung disease such as P. aeruginosa, MRSA, S. aureus, B. 362 
cenocepacia, and M. abscessus in patients receiving novel therapies will be 363 
important.  Additionally investigators must be aware of the presence of organisms 364 
currently not associated with chronic CF lung infection which may be found with 365 
increasing prevalence in clinical trials of novel therapies.    366 
 367 
The ability to accurately and reliably categorize CF patients, as having acquired an 368 
“emerging” pathogen or as having “eradicated” an existing infection, pivots on the 369 
intrinsic ability of clinical microbiology techniques to detect important shifts in patient 370 
microbiologic status. CF clinical microbiology laboratories are encouraged to follow 371 
best practice guidelines, as documented in the CUMITECH 43 guidelines (58), as 372 
well as the UK Cystic Fibrosis Trust Consensus Guidelines “Laboratory standards for 373 
processing microbiological samples from people with cystic fibrosis”(59).  However, 374 
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application of these largely culture-based techniques may not be optimal to address 375 
issues of sensitivity and specificity to support microbiological status shifts, while 376 
other testing modalities (e.g. PCR or microbiome analysis) may allow greater 377 
precision.   378 
As we move forward with clinical trials in CF lung disease it will be important for data 379 
safety monitoring boards to insist on the careful gathering of microbiology data.   380 
 381 
1. Given the current technology and the understanding that specific organisms 382 
dominate the CF lung microbiome, predominant organisms even when they 383 
represent “normal flora” should be identified.   384 
2. It will also be useful to establish reference laboratories similar to the national 385 
Burkholderia cepacia reference laboratories where organisms such as P. 386 
aeruginosa, MRSA, M. abscessus and perhaps others can be genotyped to 387 
determine if specific clones which may be more virulent are emerging as a result of 388 
specific therapies.   389 
3. Microbiome analysis should be considered once a firm interpretative standard 390 
is available which can be used to determine if a particular therapy is associated with 391 
adverse alteration of the CF microbiome.    392 
 393 
  394 
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